Test Price
2,800 AED✅ Home Collection Available
FRAS1 Gene (Fraser Syndrome) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM – 11 PM).
Clinical Guidance: Post-test telephonic interpretation with a DHA-licensed Consultant Medical Geneticist.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Price: 2,800 AED
Turnaround Time: 21–28 business days (expedited options available)
Reporting: Comprehensive clinical report with ACMG-classified variants
Test Overview & Methodology
This next-generation sequencing test examines the entire FRAS1 gene to confirm or exclude a diagnosis of Fraser syndrome—a rare autosomal recessive disorder characterized by cryptophthalmos, syndactyly, and renal agenesis. Complete coverage of all coding exons and flanking intronic regions (±20 bp) ensures detection of single nucleotide variants, small insertions/deletions, and copy number variations.
| Feature | This FRAS1 NGS Test | Traditional Sanger Sequencing |
|---|---|---|
| Precision | 99.9% analytical sensitivity; full gene coverage | ~98% sensitivity; may miss deep intronic variants |
| Methodology | NGS (Illumina NovaSeq 6000) with bioinformatic CNV detection | Single amplicon Sanger sequencing |
| Turnaround Time | 3–4 weeks (expedited available) | 4–6 weeks typical |
| Variant Interpretation | ACMG guidelines, DHA-approved report | Laboratory-specific classification |
Physician Insight & Safety Protocols
“A positive FRAS1 genetic diagnosis empowers families with clarity for recurrence risk counselling and prenatal decision-making. However, a negative test in a clinically suspected case does not exclude the syndrome; biochemical assays and imaging remain essential. I urge patients to always discuss results with a clinical geneticist before making healthcare choices.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License 9294403
Advisory & Precautions
Clinical Notice: Do not discontinue prescribed medication or modify treatment regimens without prior consultation with your physician.
Genetic counselling is mandatory before and after testing as per DHA Genomic Testing Policy. A pre-test session ensures informed consent and pedigree documentation.
Exclusion Criteria & Emergency Red Flags
- Exclusion criteria: Individuals unable to provide informed consent (minors without legal guardian consent), patients with uncorrected coagulopathy, or those who have received whole blood transfusion within 3 weeks.
- Specimen collection safety: Venipuncture is performed by DHA-licensed phlebotomists; FTA card drops require no needle for already extracted DNA.
- ER red flags: Seek immediate medical attention if you experience excessive bleeding, fainting, rapid swelling at puncture site, or signs of infection (redness, warmth, pus) within 24 hours of sample collection.
Patient FAQ & Clinical Guidance
1. What is the FRAS1 NGS test used for?
This test identifies disease-causing variants in the FRAS1 gene, confirming Fraser syndrome in a clinically suspected individual—an essential step for accurate genetic counselling and management.
2. How is the sample collected and what is the turnaround time?
A home phlebotomist collects 2–3 ml of blood in an EDTA tube or a single drop on an FTA card; the NGS results are delivered in 21–28 business days. Expedited processing is available upon request.
3. Does a negative result rule out Fraser syndrome?
No—a negative genetic test does not completely exclude the syndrome because another undetectable gene or non-coding variant may be responsible; clinical assessment remains paramount.
4. Who should consider this test?
This test is recommended for individuals with clinical features suggestive of Fraser syndrome (cryptophthalmos, syndactyly, renal agenesis), couples with a family history, or prenatal cases with ultrasound anomalies.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genomic data handling complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Medical Liability: Clinical testing safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Accreditations: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). DHA Facility License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab Branding: DNA Labs UAE.
Clinical & Logistical Metadata
| Test Name | FRAS1 Gene (Fraser Syndrome) Genetic Test by NGS |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 business days |
| Sample Type / Matrix | Whole Blood (EDTA) or Dried Blood Spot (FTA card) |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina NovaSeq 6000 |
| ICD-10-CM Code | Q87.0 (Congenital malformation syndromes predominantly affecting facial appearance) |
| LOINC Code | 85403-8 (FRAS1 gene mutation analysis in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians